About | Free Trial

Last Update

2014-02-11T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Background Information

Employment History

Vice President of Chemistry
Actokine Therapeutics

Avalon Pharmaceuticals , Inc.

Faculty
Department of Pharmaceutical Technology and Biochemistry

Vice President
Biologics

Member, Molecular Aspects of Drug Design Team
National Cancer Institute

Education

PhD
Medicinal Chemistry
Technical University of Gdansk

Web References (4 Total References)


Actokine Therapeutics

www.actokine.com [cached]

Vice President of Chemistry- Marek Cholody, PhD

...
Vice President of Chemistry - Marek Cholody, PhD Dr. Cholody has been involved in drug discovery for over 20 years. Upon completion of his PhD in Medicinal Chemistry at the Technical University of Gdansk, Poland, he joined the faculty of the Department of Pharmaceutical Technology and Biochemistry where he conducted research focused on the design and synthesis of small molecule anticancer agents. This led to the discovery of a new class of drugs - the imidazoacridones. The leading compound in this class, C-1311, is presently in Phase 2 clinical trials under the name Symadex. In 1993, Dr. Cholody joined the Molecular Aspects of Drug Design team at the National Cancer Institute, where he discovered and developed two new classes of potential anticancer and anti-AIDS agents. In 2001, he joined Avalon Pharmaceuticals as a Research Group Leader in the Medicinal Chemistry Department where he was instrumental in establishing and validating Avalon's gene expression-based drug discovery platform. His work at Avalon led to AVN316 which was nominated as clinical candidate in company's beta-catenin program. Dr. Cholody is an expert in DNA-interacting anticancer agents. He has published 26 papers and has 9 issued patents on anticancer drugs.


Actokine Therapeutics

www.actokine.com [cached]

Vice President of Chemistry- W. Marek Cholody, PhD Vice President of Biologics - Green Zhang, PhD

...
Vice President of Chemistry - W. Marek Cholody, PhD Dr. Cholody has been involved in drug discovery for over 20 years. Upon completion of his PhD in Medicinal Chemistry at the Technical University of Gdansk, Poland, he joined the faculty of the Department of Pharmaceutical Technology and Biochemistry where he conducted research focused on the design and synthesis of small molecule anticancer agents. This led to the discovery of a new class of drugs - the imidazoacridones. The leading compound in this class, C-1311, is presently in Phase 2 clinical trials under the name Symadex. In 1993, Dr. Cholody joined the Molecular Aspects of Drug Design team at the National Cancer Institute, where he discovered and developed two new classes of potential anticancer and anti-AIDS agents. In 2001, he joined Avalon Pharmaceuticals as a Research Group Leader in the Medicinal Chemistry Department where he was instrumental in establishing and validating Avalon's gene expression-based drug discovery platform. His work at Avalon led to AVN316 which was nominated as clinical candidate in company's beta-catenin program. Dr. Cholody is an expert in DNA-interacting anticancer agents. He has published 26 papers and has 9 issued patents on anticancer drugs.


International Drug Discovery Science and Technology (IDDST) 2008

www.iddst.com [cached]

Dr. Wieslaw Marek Cholody, Research Group Leader, Avalon Pharmaceuticals, Inc, USA


Dr. Wieslaw Marek Cholody, ...

www.iddst.com [cached]

Dr. Wieslaw Marek Cholody, Research Group Leader, Avalon Pharmaceuticals, Inc, USA

Similar Profiles

Other People with this Name

Other people with the name Cholody

Patrycjusz Cholody
Pentair Inc

Iwona Chołody
IVEX

Krystian Chołody
Stanley

Courtney Cholody
JR Turnbull Communications

Gitte Cholody
Novo Nordisk Inc

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory